Mutual of America Capital Management LLC Has $4.75 Million Stock Holdings in Repligen Co. (NASDAQ:RGEN)

Mutual of America Capital Management LLC decreased its stake in Repligen Co. (NASDAQ:RGEN) by 5.1% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 31,913 shares of the biotechnology company’s stock after selling 1,719 shares during the quarter. Mutual of America Capital Management LLC owned approximately 0.06% of Repligen worth $4,749,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Andra AP fonden acquired a new stake in shares of Repligen in the second quarter valued at approximately $25,000. International Assets Investment Management LLC acquired a new stake in Repligen during the 2nd quarter worth $33,000. UMB Bank n.a. raised its position in shares of Repligen by 138.3% during the third quarter. UMB Bank n.a. now owns 224 shares of the biotechnology company’s stock worth $33,000 after purchasing an additional 130 shares during the period. Lazard Asset Management LLC lifted its stake in Repligen by 206.1% in the first quarter. Lazard Asset Management LLC now owns 202 shares of the biotechnology company’s stock valued at $36,000 after buying an additional 136 shares in the last quarter. Finally, Blue Trust Inc. lifted its position in Repligen by 113.4% in the 3rd quarter. Blue Trust Inc. now owns 239 shares of the biotechnology company’s stock valued at $36,000 after acquiring an additional 127 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the stock. Benchmark restated a “hold” rating on shares of Repligen in a research note on Monday, August 5th. StockNews.com raised shares of Repligen from a “sell” rating to a “hold” rating in a report on Wednesday, November 13th. Wells Fargo & Company assumed coverage on Repligen in a research report on Tuesday, August 27th. They issued an “overweight” rating and a $180.00 price target on the stock. JPMorgan Chase & Co. boosted their price objective on shares of Repligen from $190.00 to $200.00 and gave the company an “overweight” rating in a research report on Wednesday, July 31st. Finally, Wolfe Research initiated coverage on shares of Repligen in a report on Thursday, November 14th. They issued a “peer perform” rating for the company. Four investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the company’s stock. According to MarketBeat.com, Repligen currently has an average rating of “Moderate Buy” and a consensus target price of $190.25.

Repligen Trading Up 8.1 %

Shares of RGEN opened at $138.90 on Thursday. The company has a current ratio of 6.65, a quick ratio of 5.56 and a debt-to-equity ratio of 0.26. The firm has a market capitalization of $7.78 billion, a price-to-earnings ratio of -375.41, a PEG ratio of 3.75 and a beta of 0.96. The firm’s 50-day moving average price is $140.30 and its 200-day moving average price is $143.67. Repligen Co. has a 1-year low of $113.50 and a 1-year high of $211.13.

Repligen (NASDAQ:RGEN) last issued its earnings results on Tuesday, November 12th. The biotechnology company reported $0.43 earnings per share for the quarter, topping analysts’ consensus estimates of $0.34 by $0.09. Repligen had a positive return on equity of 3.92% and a negative net margin of 3.36%. The business had revenue of $154.87 million during the quarter, compared to analyst estimates of $153.34 million. During the same quarter in the previous year, the firm earned $0.23 EPS. Repligen’s revenue was up 9.7% on a year-over-year basis. Sell-side analysts anticipate that Repligen Co. will post 1.52 EPS for the current year.

Insiders Place Their Bets

In related news, Director Anthony Hunt sold 22,191 shares of the company’s stock in a transaction dated Tuesday, September 10th. The shares were sold at an average price of $145.37, for a total value of $3,225,905.67. Following the completion of the sale, the director now directly owns 139,840 shares of the company’s stock, valued at $20,328,540.80. This represents a 13.70 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 1.20% of the stock is currently owned by corporate insiders.

Repligen Company Profile

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products.